Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
11/18/2008
 
First Published:
12/22/2004
1.
Phase III Randomized Study of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Single Agent Therapy in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0406049-01
CTI-PIX301, NCT00101049
Last Modified:
5/21/2008
 
First Published:
10/18/2007
2.
Phase III Randomized Study of Fludarabine Phosphate and Rituximab With Versus Without Pixantrone in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
CTI-CRRI 0807003
CRRI 0807003, NCT00551239
3.
Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
PIX109
NCT00106600
Last Modified:
11/23/2004
 
First Published:
9/24/2003
4.
Phase II Study of Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
THERADEX-AZA-II-02
CWRU-NOVU-1403, SUNY-HSC-4849, NOVUSPHARMA-AZA-II-02, NCT00069966
Last Modified:
8/1/2006
 
First Published:
3/24/2003
5.
Phase I Study of Pixantrone, Fludarabine, Dexamethasone, and Rituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
THERADEX-AZA-I-06
NOVUSPHARMA-AZA-I-06, NCT00060684
Last Modified:
3/19/2003
 
First Published:
12/21/2002
6.
Phase I Study of Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 to 64
Pharmaceutical / Industry
THERADEX-AZA-I-05
NOVUSPHARMA-AZA-I-05, NOVUSPHARMA-AZA-1401, CWRU-050213J, NCT00053105
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute